<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03584724</url>
  </required_header>
  <id_info>
    <org_study_id>Norflo-Oro-16</org_study_id>
    <nct_id>NCT03584724</nct_id>
  </id_info>
  <brief_title>Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis</brief_title>
  <official_title>Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis: a Multicenter Randomized, Placebo Controlled, Double-blind Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bascom Palmer Eye Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eye Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the efficacy of Norflo Oro in the treatment of
      relapsing autoimmune uveitis (RAU), measured as a long term reduction of the frequency and
      the severity of relapses, in patients with HLA-B27 associated uveitis, under conditions of
      routine medical practice. The reduction of the mean number of relapses per patient between
      the year before study treatment and the study period will also be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objective of this study will be: (i) evaluation of the improvement of side
      effects due to HLA-B27 associated uveitis such as intraocular pressure (IOP), cystoid macular
      edema, keratophaty and synechia (ii) evaluation of the improvement in uveitis-related
      symptoms: BCVA and symptoms measured by VAS, like ocular pain, photophobia, floaters and
      blurred vision; (iii) evaluation of cell damage and inflammation reduction in patients with
      HLA-B27 associated uveitis; (iv) evaluation of the patients' attitude towards the study
      treatment and also the evaluation of the safety profile of the study product.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Up to 60 eligible patients will be randomly assigned to NORFLO® ORO or placebo treatment groups in a 1:1 ratio using a stratified randomization blocks scheme.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The reduction of the mean number of relapses per patient between the year before treatment and the study period.</measure>
    <time_frame>12 months</time_frame>
    <description>The primary statistical hypothesis to be assessed in this study is whether there is a difference in cell damage and inflammation reduction between the treatment group and placebo group. The cell damage and inflammation reduction will be measured by Laser Flare Meter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The improvement of side effects due to HLA-B27-associated uveitis</measure>
    <time_frame>12 months</time_frame>
    <description>The improvement of side effects due to HLA-B27-associated uveitis, such as intraocular pressure between NORFLO® ORO treatment group and control group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>Norflo Oro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Box of 30 packets of Norflo Oro. The study subject will take the entire content of one packet with meal twice per day. The study subject will be evaluated in a total of three visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for Norflo Oro</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Box of 30 packets of Placebo. The study subject will take the entire content of one packet with meal twice per day. The study subject will be evaluated in a total of three visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norflo Oro</intervention_name>
    <description>Norflo Oro is highly bioavailable curcumin complexed into phytosomes</description>
    <arm_group_label>Norflo Oro</arm_group_label>
    <other_name>Meriva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Norflo Oro</intervention_name>
    <description>Placebo consist of look-alike single foil pouches without active ingredient of Norflo.</description>
    <arm_group_label>Placebo for Norflo Oro</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of HLA-B27 positive related uveitis in non- acute phase

          -  At least one autoimmune uveitis relapse

        Exclusion Criteria:

          -  Use of supplements (nutraceuticals) or systemic therapy for uveitis with
             anti-inflammatory immunosuppressive or biological drugs within last 30 days

          -  Anticipated need for systemic anti-inflammatory treatment during the study

          -  Use of intravitreal peribulbar, sub-tenon, periocular injection in the previous 6
             months

          -  Long-term treatment with a systemic anti-inflammatory, immune suppressant drugs

          -  Woman taking hormonal contraceptives, pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pia Allegri</last_name>
    <role>Principal Investigator</role>
    <affiliation>S.S. Uveitis Center, Rapallo Hospital, Genoa- Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Steigerwalt R, Nebbioso M, Appendino G, Belcaro G, Ciammaichella G, Cornelli U, Luzzi R, Togni S, Dugall M, Cesarone MR, Ippolito E, Errichi BM, Ledda A, Hosoi M, Corsi M. Meriva®, a lecithinized curcumin delivery system, in diabetic microangiopathy and retinopathy. Panminerva Med. 2012 Dec;54(1 Suppl 4):11-6.</citation>
    <PMID>23241930</PMID>
  </reference>
  <reference>
    <citation>Mazzolani F, Togni S. Oral administration of a curcumin-phospholipid delivery system for the treatment of central serous chorioretinopathy: a 12-month follow-up study. Clin Ophthalmol. 2013;7:939-45. doi: 10.2147/OPTH.S45820. Epub 2013 May 22.</citation>
    <PMID>23723686</PMID>
  </reference>
  <results_reference>
    <citation>Allegri P, Mastromarino A, Neri P. Management of chronic anterior uveitis relapses: efficacy of oral phospholipidic curcumin treatment. Long-term follow-up. Clin Ophthalmol. 2010 Oct 21;4:1201-6. doi: 10.2147/OPTH.S13271.</citation>
    <PMID>21060672</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2018</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HLA-B27</keyword>
  <keyword>relapses</keyword>
  <keyword>curcumin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

